Benzinga · Aug 11, 2026
Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $7
Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $9 to $7.
MG
NASDAQ · MGX
Metagenomi, Inc. Common Stock
Healthcare · Biotechnology
$1.23
Up+$0.03 (+2.50%)
Updated Aug 23, 2026, 12:55 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 65.71M
- P/E ratio
- -0.75
- Dividend yield
- 0.00%
- 52-week range
- $1.13 – $1.83
- Volume
- 303.2K
- Avg. volume
- 672.12K
Price performance
MGX price history
1M range · 20 trading sessions · Daily adjusted prices
MGX closed at $1.23 after 20 trading sessions, up 1.65% for the selected period.
- Last close
- $1.23
- Period change
- +1.65%
- Period low
- $1.19
- Period high
- $1.24
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $1.22 | $1.26 | $1.20 | $1.23 | 303.2K |
| Aug 20, 2026 | $1.21 | $1.25 | $1.20 | $1.20 | 107.02K |
| Aug 19, 2026 | $1.21 | $1.25 | $1.21 | $1.24 | 248.13K |
| Aug 18, 2026 | $1.23 | $1.24 | $1.2042 | $1.21 | 66.49K |
| Aug 17, 2026 | $1.23 | $1.24 | $1.215 | $1.22 | 119.44K |
| Aug 14, 2026 | $1.22 | $1.24 | $1.20 | $1.23 | 83.5K |
| Aug 13, 2026 | $1.21 | $1.25 | $1.21 | $1.23 | 267.29K |
| Aug 12, 2026 | $1.21 | $1.22 | $1.195 | $1.22 | 91.29K |
| Aug 11, 2026 | $1.18 | $1.2457 | $1.18 | $1.21 | 133.11K |
| Aug 10, 2026 | $1.23 | $1.24 | $1.21 | $1.23 | 151.59K |
| Aug 7, 2026 | $1.24 | $1.248 | $1.225 | $1.23 | 142.97K |
| Aug 6, 2026 | $1.22 | $1.24 | $1.2125 | $1.24 | 146.31K |
| Aug 5, 2026 | $1.22 | $1.225 | $1.2012 | $1.215 | 77.22K |
| Aug 4, 2026 | $1.20 | $1.23 | $1.20 | $1.21 | 110.96K |
| Aug 3, 2026 | $1.19 | $1.24 | $1.19 | $1.21 | 134.05K |
| Jul 31, 2026 | $1.21 | $1.2201 | $1.185 | $1.19 | 135.77K |
| Jul 30, 2026 | $1.20 | $1.23 | $1.20 | $1.22 | 132.8K |
| Jul 29, 2026 | $1.21 | $1.215 | $1.20 | $1.21 | 35.45K |
| Jul 28, 2026 | $1.21 | $1.23 | $1.20 | $1.21 | 111.09K |
| Jul 27, 2026 | $1.21 | $1.235 | $1.20 | $1.21 | 68.24K |
Latest MGX news
The latest Smart Investors Daily articles mentioning MGX.
Stock researchCompany · Overview
MGX research
Overview
Company profile and research snapshot.
Company profile
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $14.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | Wells Fargo | Overweight | — |
| Jul 7, 2026 | Chardan Capital | Buy | — |
| May 12, 2026 | Wells Fargo | Overweight | — |
| Aug 19, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 15, 2025 | Chardan Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 10, 2026
Metagenomi Q2 EPS $(0.73) Misses $(0.57) Estimate, Sales $(257.000K) Miss $2.960M Estimate
Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.57) by 28.07 percent. This is a 35.19 percent decrease over losses of $(0.54) per share from the
Benzinga · Jul 7, 2026
Chardan Capital Maintains Buy on Metagenomi Therapeutics, Lowers Price Target to $5
Chardan Capital analyst Keay Nakae maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Buy and lowers the price target from $7 to $5.
Benzinga · Mar 5, 2026
Metagenomi Therapeutics Q4 Earnings Assessment
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
